Diagnostic and Prognostic Value of Circulating miR-221 for Extranodal Natural Killer/T-Cell Lymphoma

Guo, Honglei; Huang, Guoliang; Guo, Chengcheng; Pu, Xingxiang; Lin, Tong

doi:10.1155/2010/474692

Cited by 65 publications

(64 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Lawrie and colleagues found that serum levels of miR-155, miR-210, and miR-21 were higher in patients with diffuse large B-cell lymphoma (DLBCL) than control sera, and high expression was associated with reduced relapsefree survival (8). Elevated serum levels of miR-155 in DLBCL were validated in a subsequent study (13) and circulating miR-221 was raised pretherapy in extra nodal natural killer/T-cell Lymphoma (14). However, in these three studies, no sequential samples were taken to investigate whether serial monitoring may have clinical utility as disease response biomarkers.…”

Section: Introductionmentioning

confidence: 99%

Plasma MicroRNA Are Disease Response Biomarkers in Classical Hodgkin Lymphoma

Jones

Nourse

Keane

et al. 2014

Clinical Cancer Research

116

View full text Add to dashboard Cite

Purpose: Although microRNAs (miRNA) show potential as diagnostic biomarkers in cancer, their role as circulating cell-free disease response biomarkers remains unknown. Candidate circulating miRNA biomarkers for classical Hodgkin lymphoma (cHL) might arise from Hodgkin-Reed-Sternberg (HRS) cells and/or nonmalignant tumor-infiltrating cells. HRS cells are sparse within the diseased node, embedded within a benign microenvironment, the composition of which is distinct from that seen in healthy lymph nodes.Experimental Design: Microarray profiling of more than 1,000 human miRNAs in 14 cHL primary tissues and eight healthy lymph nodes revealed a number of new disease node-associated miRNAs, including miR-494 and miR-1973. Using quantitative real-time PCR (qRT-PCR), we tested the utility of these, as well as previously identified disease node-associated plasma miRNAs (including miR-21 and miR-155), as disease response biomarkers in a prospective cohort of 42 patients with cHL. Blood samples were taken in conjunction with radiologic imaging at fixed time points before, during, and after therapy. Absolute quantification was used so as to facilitate implementation in diagnostic laboratories.Results: Levels of miR-494, miR-1973, and miR-21 were higher in patients than control (n ¼ 20) plasma (P ¼ 0.004, P ¼ 0.007, and P < 0.0001, respectively). MiR-494 and miR-21 associated with Hasenclever scores !3. Strikingly, all three miRNAs returned to normal at remission (P ¼ 0.0006, P ¼ 0.0002, and P < 0.0001 respectively). However, only miR-494 and miR-1973 reflected interim therapy response with reduction being more pronounced in patients achieving complete versus partial responses (P ¼ 0.043 and P ¼ 0.0012, respectively).Conclusion: Our results demonstrate that in patients with cHL, circulating cell-free miRNAs can reflect disease response once therapy has commenced. Clin Cancer Res; 20(1); 253-64. Ó2013 AACR.

show abstract

Section: Introductionmentioning

confidence: 99%

Plasma MicroRNA Are Disease Response Biomarkers in Classical Hodgkin Lymphoma

Jones

Nourse

Keane

et al. 2014

Clinical Cancer Research

116

View full text Add to dashboard Cite

show abstract

“…In prostate cancer, circulating levels of miR-141 along with 15 other microRNAs (miR-16, miR-92a, miR-92b, miR-103, miR-107, miR-197, miR-34b, miR-328, miR-485-3p, miR-486-5p, miR-574-3p, miR-636, miR-640, miR-766, and miR-885-5p) have been found to be higher in patients than in healthy controls [21,26]. In addition, circulating miR-221 has been shown to be higher in patients with ovarian cancer, melanoma, and lymphoma compared to healthy controls [27,28,29]. Taken together these studies suggest that microRNA biomarkers may be more sensitive than current circulating protein biomarkers, and than imaging techniques in cancer diagnosis (Table 1).…”

Section: Micrornas As Biomarkersmentioning

confidence: 99%

Circulating MicroRNAs as Biomarkers and Mediators of Cell–Cell Communication in Cancer

Taylor

2015

Biomedicines

View full text Add to dashboard Cite

Abstract:The realization of personalized medicine for cancer will rely not only on the development of new therapies, but on biomarkers that direct these therapies to the right patient. MicroRNA expression profiles in the primary tumor have been shown to differ between cancer patients and healthy individuals, suggesting they might make useful biomarkers. However, examination of microRNA expression in the primary tumor requires an invasive biopsy procedure. More recently, microRNAs have been shown to be released from the primary tumor into the circulation where they can be utilized as non-invasive biomarkers to diagnose patients, predict prognosis, or indicate therapeutic response. This review provides an overview of the current use of circulating microRNAs as biomarkers as well as recent findings on their role in regulating cell signaling interactions in the tumor microenvironment.

show abstract

“…109 Plasma miR-221 has been found to be a good diagnostic and prognostic marker for extranodal natural killer T-cell lymphoma. 110 Clearly, although the results are very preliminary, the ability of miRNAs to act as noninvasive biomarkers of BCLs is a promising prospect.…”

Section: Mirnas As Noninvasive Biomarkers Of B-cell Lymphomamentioning

confidence: 99%

MicroRNAs as B-cell lymphoma biomarkers

Manterola¹,

Fernández-Mercado²,

Larrea³

et al. 2015

BLCTT

View full text Add to dashboard Cite

B-cell lymphomas represent a group of more than 35 recognized mature B-cell neoplasms differentiated largely on the basis of immunohistochemical staining patterns that are often challenging to accurately diagnose. Despite having been only formally recognized just over 10 years ago, microRNAs (miRNAs) have become one of the trendiest topics in biology. Dysregulation of miRNAs is a ubiquitous feature of cancer in general, including B-cell lymphomas. Many of the miRNAs aberrantly expressed in B-cell lymphomas also play a crucial regulatory role in normal hematopoietic function. MiRNAs show great potential as novel biomarkers of cancer, as they can differentiate cancers according to diagnosis and developmental stage, even discriminating between cancers that are poorly separated histologically. Furthermore, they can be robustly measured from routinely prepared formalin-fixed paraffin-embedded biopsy material and biological fluids such as blood. Here, we consider the identity, function, and biomarker potential of miRNAs in B-cell lymphomas and, most importantly, the hurdles that remain to be overcome if they are really to become part of future clinical practice.

show abstract

Diagnostic and Prognostic Value of Circulating miR-221 for Extranodal Natural Killer/T-Cell Lymphoma

Cited by 65 publications

References 23 publications

Plasma MicroRNA Are Disease Response Biomarkers in Classical Hodgkin Lymphoma

Plasma MicroRNA Are Disease Response Biomarkers in Classical Hodgkin Lymphoma

Circulating MicroRNAs as Biomarkers and Mediators of Cell–Cell Communication in Cancer

MicroRNAs as B-cell lymphoma biomarkers

Contact Info

Product

Resources

About